Hyderabad, India and Princeton, NJ, USA. July 11, 2018— Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Hydroxychloroquine Sulfate Tablets USP, 200 mg, a therapeutic equivalent generic version of Plaquenil® (hydroxychloroquine sulfate) Tablets, in the U.S. market, approved by the U.S. Food and Drug Administration (USFDA).
The Plaquenil® brand and generic had U.S. sales of approximately $215 million MAT for the most recent twelve months ending in May 2018 according to IMS Health*.
Dr. Reddy’s Hydroxychloroquine Sulfate Tablets are available in 200 mg tablets in the bottle count sizes of 100 and 500.
Plaquenil® is a trademark of Concordia International Corp.
Your email address will not be published. Required fields are marked *
Returning John McGuinness heads impressive line up for Bennetts Senior Classic TT Race
Wikipedia volunteers and free knowledge leaders gather in Cape Town for the first annual “Wikimania” conference in sub-saharan Africa
Wikimedia Foundation announces Tanya Capuano as new Trustee, alongside leadership appointments at 14th annual Wikimania
Honda launches 2018 edition NAVi
YES BANK becomes 1st Bank in India to Partner Maharashtra Smart Cities to Tackle Urban Development Challenges, Bosch and Dell EMC Pledge Support
2014 The Global Indian New Network (TGINN)